For patients with EGFR-mutant NSCLC who progress on osimertinib, do you repeat tumor molecular profiling?
If so do you favor repeat tumor biopsy or cfDNA?
Answer from: Medical Oncologist at Academic Institution
I do favor repeating a tumor biopsy in patients that progress on osimertinib. If I send cfDNA that would be concurrently not instead of tumor tissue. The mechanisms of resistance to osimertinib are many including the emergence of C797S mutation, MET amplification, HER2 amplification, BRAF 600E mutat...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
I agree with Dr. Jalal that tissue is important in the EGFR space for small cell transformation documentation as a resistant mechanism to TKI's and is also interesting that p53 and RB mutations in ctDNA can be a clue to SCLC transformation.
Comments
Medical Oncologist at Kettering Cancer Center
Tissue biopsy continues to be the gold standard an...
Tissue biopsy continues to be the gold standard an...
Medical Oncologist at Siri Onclogy and hematology Infusion Service
This is one space, like many others, do not do the...
This is one space, like many others, do not do the...
Medical Oncologist at West Virginia University Cancer Institute
Agree. In EGFR at progression with osimertinib as ...
Agree. In EGFR at progression with osimertinib as ...